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Abstract
Intestinal mesenchymal cells deposit extracellular matrix in fibrotic Crohn's disease
(CD). The contribution of epithelial to mesenchymal transition (EMT) to the mes-
enchymal cell pool in CD fibrosis remains obscure. The miR‐200 family regulates
fibrosis‐related EMT in organs other than the gut. E‐cadherin, cytokeratin‐18 and
vimentin expression was assessed using immunohistochemistry on paired strictured
(SCD) and non‐strictured (NSCD) ileal CD resections and correlated with fibrosis
grade. MiR‐200 expression was measured in paired SCD and NSCD tissue compart-
ments using laser capture microdissection and RT‐qPCR. Serum miR‐200 expression
was also measured in healthy controls and CD patients with stricturing and non‐
stricturing phenotypes. Extra‐epithelial cytokeratin‐18 staining and vimentin‐positive
epithelial staining were significantly greater in SCD samples (P = 0.04 and P = 0.03,
respectively). Cytokeratin‐18 staining correlated positively with subserosal fibrosis
(P < 0.001). Four miR‐200 family members were down‐regulated in fresh SCD sam-
ples (miR‐141, P = 0.002; miR‐200a, P = 0.002; miR‐200c, P = 0.001; miR‐429;
P = 0.004); miR‐200 down‐regulation in SCD tissue was localised to the epithelium
(P = 0.001‐0.015). The miR‐200 target ZEB1 was up‐regulated in SCD samples
(P = 0.035). No difference in serum expression between patient groups was
observed. Together, these observations suggest the presence of EMT in CD stric-
tures and implicate the miR‐200 family as regulators. Functional studies to prove
this relationship are now warranted.
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1 | INTRODUCTION
Crohn's disease (CD) is a chronic, inflammatory, relapsing and remit-
ting condition that predominantly affects the gastrointestinal tract.
Research focussed on intestinal barrier function, host immune
responses, genetic susceptibility and the gut microbiota has
advanced our understanding of the aetiopathogenesis of inflamma-
tory CD. In contrast, the mechanisms responsible for the formation
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of fibrotic strictures in fibrostenosing CD are not well defined. The
estimated lifetime risk of surgery for patients with CD is approxi-
mately 70%1,2 and fibrostenosing disease is the most common surgi-
cal indication. Surgery is not only costly for healthcare systems3 but
is associated with unemployment and poorer quality of life scores
for patients.4 Current medical therapies are unable to reverse estab-
lished fibrosis and the prediction of stricture development remains a
significant clinical challenge. Moreover, the rates of progression to
stricturing disease have not altered despite the introduction and sub-
sequent widespread use of biological therapy.5
Intestinal mesenchymal cells play a pivotal role in deposition of
extracellular matrix that characterises fibrosis in CD.6,7 Manipulating
the accumulation and function of intestinal mesenchymal cells is an
attractive therapeutic option for fibrostenosing CD. Potential mecha-
nisms of mesenchymal cell accumulation include expansion of the
resident cell population, recruitment of bone marrow‐derived circu-
lating fibrocytes, and epithelial to mesenchymal transition (EMT).8
EMT is a process in which epithelial cells lose cellular adhesion and
acquire mesenchymal morphology, together with an increased migra-
tory phenotype. Epithelial‐specific cellular markers are lost whilst
mesenchymal markers are gained. The loss of e‐cadherin, a cell adhe-
sion molecule responsible for adherens junction integrity,9,10 appears
to be a necessary step for EMT to occur.11
EMT has been heavily implicated in both cancer progression
(type 3 EMT)12-14 and the development of tissue fibrosis (type 2
EMT). The latter has been demonstrated in renal,15-19 hepatic,20-22
pulmonary23,24 and cardiac25,26 models. Two recent studies of type
2 EMT have provided evidence for the concept of “partial EMT”27,28
whereby cells lose epithelial characteristics but promote fibrosis by
means other than the active deposition of extracellular matrix within
the deeper tissue layers. These include the secretion of exosomes
and cytokines to promote the differentiation of fibroblasts to myofi-
broblasts and the recruitment of bone‐marrow derived mesenchymal
cells. In one study these transitioning cells were found close to the
epithelial layer from which they had originated.27 This concept of
“partial EMT” is thought occur predominantly in type 2, rather than
type 3, EMT.27,29 It is possible that this is the case in intestinal
fibrosis, although comparatively few studies have been performed
examining the role of EMT in this setting. Cell fate mapping in a
murine colitis model demonstrated double‐labelled intestinal epithe-
lial cells for both epithelial‐specific and mesenchymal‐specific cellular
markers.30 In addition, high levels of nuclear β‐catenin localisation
and expression of the transcription factor SLUG, which can both
be associated with EMT, were reported in human CD intestinal
samples.31
MiRNAs regulate EMT by negative post‐transcriptional control of
target gene expression. The miR‐200 family impacts on fibrosis‐related
EMT in organs other than the intestine.32-35 MiR‐200b overexpression
leading to suppression of TGFβ‐induced EMT alterations has been
demonstrated in an intestinal epithelial cell line.36 In addition, down‐
regulation of the miR‐200 family and altered expression of the EMT
effectors SNAIL and SLUG has been reported in colonic tissue from
patients with CD.37 In this study, we examined well‐characterised
intestinal CD specimens for the presence of EMT by quantifying
cellular marker expression and related this to the histological
degree of fibrosis. We also confirmed dysregulation of the miR‐200
family and downstream effectors in fibrotic samples and demon-
strate that the former is specific to the intestinal epithelium.
Finally, we assessed serum levels of the miR‐200 family in different
CD phenotypes.
2 | METHODS
2.1 | Patient recruitment
Patients at Barts Health NHS Trust with a documented history of
stricturing ileal CD undergoing surgical resection were recruited.
Any patient with fistulating disease, dysplasia or cancer (previous
or current) was excluded. Patients were consented under ethical
approval granted by the Health Research Authority (REC reference
13/LO/1292) specifically for this study. Data on age, gender, smok-
ing status, disease duration, disease location, medications, previous
surgery and inflammatory markers were collected. Areas of stricture
(SCD) and non‐stricture (NSCD) were identified and harvested by
histopathologists then stored in RNA Later (Qiagen, UK) prior to
RNA extraction.
For the serum miRNA expression studies, samples from healthy
controls (n = 13) and patients with CD (n = 42) were provided, along
with a database of clinical characteristics, by colleagues from the
Department of Internal Medicine, San Matteo Hospital (Pavia, Italy)
as described previously.38 CD patients were either classified as SCD
(with a stricturing phenotype) or NSCD (with either an inflammatory
or penetrating phenotype).
2.2 | Immunohistochemistry
Archived small intestinal resection specimens from patients with
stricturing CD were identified from the Barts Health NHS Trust
histopathology database. Pathology reports were interrogated and
blocks containing SCD and NSCD tissue for each patient chosen.
4 μm thick sections of formalin‐fixed paraffin‐embedded (FFPE)
tissue were cut followed by de‐waxing, hydration and blocking in
goat serum. Primary antibodies used were anti‐e‐cadherin (Dako
Clone NCH‐28) at 1:50 dilution and 30 minutes antigen retrieval in
pH9 buffer; anti‐cytokeratin 18 (Dako Clone DC10) at 1:100 dilution
and 20 minutes antigen retrieval in pH9 buffer; anti‐vimentin
(Dako, Glostrup, Denmark) at 1:200 dilution and 30 minutes anti-
gen retrieval in pH9 buffer. Human adult appendix tissue served as
positive controls. Negative controls omitting the primary antibodies
were also included.
2.3 | Immunohistochemistry image analysis
Stained slides were scanned with the NanoZoomer 2.0 slidescanner
(Hamamatsu, Japan). Tissue areas of interest for each cellular marker
were outlined in ImageJ software in order to block out the rest of
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the image. Predetermined thresholds for pigment colour on the red‐
green‐blue spectrum, size and circularity were then applied to these
areas of interest in order to capture both background cellular coun-
terstaining and positive cellular antibody staining separately
(Table S1). These thresholds were used consistently across all sam-
ples. Images generated by the ImageJ program were also checked
visually to ensure staining included in the analysis was truly cell‐
related and not simply as a result of cellular debris or tissue artefact.
Extra‐epithelial staining of e‐cadherin and cytokeratin‐18 was mea-
sured using three randomly selected fields of lamina propria and sub-
mucosa at 20× magnification of each sample and measuring the
proportion of positive cellular staining from total counterstaining.
Vimentin staining was measured in 2 randomly selected regions of
100 consecutive surface epithelial cells as well as 3 randomly
selected crypts per slide, again at 20× magnification. Results were
expressed as area of positive staining as a percentage of total back-
ground staining. Positively stained percentage area (rather than per-
centage of cells) was used owing to merging of cell nuclei upon
cellular parameter inputting within the ImageJ program. Other easily
identifiable cell types known to also express vimentin, such as peri‐
cryptal fibroblasts and neuronal cells were visually excluded from
ImageJ analysis wherever possible.
2.4 | Histological assessment of FFPE tissue from
stricture resection specimens
A specialist gastrointestinal pathologist (RF) assessed intestinal
resection tissue sections from patients included in the study in
order to grade the relative levels of fibrosis and inflammation. The
pathologist was blinded to the clinical details. Currently, histological
scoring systems for intestinal fibrosis are sparse and are not vali-
dated. Therefore, both submucosal and subserosal fibrosis were
graded in terms of severity and extent, and each was given a nom-
inal score between 0 and 3 based on the proportion of tissue
involved. The sum of the submucosal and subserosal fibrosis scores
gave a total fibrosis score for each section. Objective assessments
of inflammation were also made by scoring ulcers (if present)
according to their severity and depth. If more than one ulcer was
present, the score of the widest and deepest ulcer was taken for-
ward. Other features that were recorded included the severity of
the transmural chronic inflammatory infiltrate (if present) and the
presence or absence of serositis.
2.5 | Laser capture micro‐dissection
Pathology reports for archived intestinal resection specimens from
patients with CD were interrogated and blocks containing SCD and
NSCD tissue for each patient chosen. Two serial 5 μm sections of
FFPE tissue were cut from each block in an RNAse‐free manner
onto nuclease‐ and human nucleic acid‐free slides covered with
polyethylene naphthalate membrane (Zeiss, Germany). Sections
were very briefly counterstained before specific tissue compart-
ments (epithelium, submucosa and muscle) were dissected and
collected into collection tubes with adhesive caps (Zeiss, Germany)
using the PALM Microbeam Laser Dissector (Zeiss, Germany). Sam-
ples were standardised by micro‐dissecting and collecting the same
surface areas for each compartment for each slide, to within a
1.5% error: 4 000 000 μm2 epithelium, 6 000 000 μm2 submucosa,
10 000 000 μm2 muscle. Tissue from two serial sections from each
block was combined and incubated overnight with proteinase K
(10 μL) and Buffer KD (150 μL) prior to total RNA extraction using
the miRNeasy FFPE Kit according to the manufacturer's protocol
(Qiagen, Hilden, Germany).
2.6 | RNA extraction, reverse transcription &
quantitative real‐time PCR of gene expression
Total RNA, including and excluding small RNAs, was extracted
using the miRNeasy and RNeasy kits (Qiagen), respectively. Reverse
transcription (RT) and quantitative real time PCR (qPCR) were per-
formed on RNA extracted from intestinal tissue using the High‐
Capacity‐RNA to cDNA kit and Taqman assays (Applied Biosystems,
Foster City, CA, USA), respectively. MiRNAs extracted from FFPE
samples using laser capture micro‐dissection (LCM) underwent RT
and qPCR using the miScript system (Qiagen) and a pre‐amplifica-
tion step owing to low RNA concentrations. Fold changes were cal-
culated using the 2−δδCT method normalised to miR‐26b as an
endogenous control for miRNA assays and GAPDH for mRNA
assays. The miScript system was used for miRNA extracted from
serum without a pre‐amplification step. The synthetic RNA spike‐in,
Ce_miR‐39_1, was added to aid data normalisation. Analysis of melt
curves was undertaken to ensure a single PCR product was
obtained at each reaction. The normalised data were then log10
transformed before statistical analysis. The 7500 Fast System Real-
Time PCR cycler (Qiagen) was used for all qPCR assays with ther-
mocycling conditions adjusted according to recommendations for
each reaction.
The following Taqman probes (Applied Biosystems) were used:
miR‐141, Hs04406459_s1; miR‐200a, Hs04231538_s1, miR‐200b,
Hs04231483_s1, miR‐200c, Hs04231534_s1; miR‐429, Hs0423
1584_s1; ZEB1, Hs00232783_m1; ZEB2, Hs00207691_m1; SNAIL,
Hs00195591_m1; TWIST, Hs01675818_s1. QPCR was performed
on micrornas extracted from intestinal tissue using laser capture
microdissection and from serum using the following miScript probes
(Qiagen): miR‐26b, MS00003234; miR‐141, MS00003507; miR‐200a,
MS00003738; miR‐200b, MS00009016; miR‐200c, MS00003752;
miR‐429, MS00004193; Ce_miR_39_1, MS00019789; miR‐451a,
MS00004242; miR‐23a, MS00031633.
2.7 | Statistics
Graphpad Prism analysis software was used to perform Student's t
tests and Pearson's correlation coefficients as denoted. A P‐value
<0.05 was considered statistically significant. Experiments were per-
formed in triplicates except for the serum quantifications which were
performed in duplicates.
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3 | RESULTS
3.1 | Patient demographics
The clinical characteristics of patients providing tissue from intesti-
nal resections are shown in Table 1. All patients presented with
either ileal (55.6%) or ileocolonic (44.4%) disease, and all had a stric-
turing phenotype. Table 2 summarises the clinical characteristics of
CD patients from whom serum samples were used for miRNA
expression profiling. Both the median age at sample collection and
disease duration were higher in the SCD group compared to the
NSCD group, although this difference was not statistically signifi-
cant. This is perhaps intuitive, given that the development of fibro-
sis usually occurs later in the disease course in CD. CDAI scores
were almost identical between the two groups (NSCD and SCD).
Similarly, there was no significant difference in the proportion of
patients prescribed systemic 5‐ASA, antibiotic, thiopurine or anti‐
TNFα treatment.
3.2 | Quantified expression patterns of cell‐specific
markers are consistent with EMT in fibrotic CD
intestinal tissue
Immunohistochemistry (IHC) staining for the epithelial‐specific cellu-
lar marker e‐cadherin revealed a highly specific epithelial pattern in
all sections of nine CD surgical sample pairs (Figure S1). However,
not a single cell positive for e‐cadherin staining was localised outside
of the epithelial architecture (0% for both NSCD and SCD sample
groups). Table 3 and Figure 1A and B show the percentages of
extra‐epithelial cells positively stained for cytokeratin‐18 as a pro-
portion of total cells stained for each specimen (raw data are shown
in Table S2). Positive cellular staining of cytokeratin‐18 within the
lamina propria and submucosa was observed in 17 of 18 specimens
(94%). The mean percentage of positively stained cells was signifi-
cantly higher in the SCD group (0.49% vs 0.15%; P = 0.043). Repre-
sentative sample images from IHC staining are shown in Figure 1C‐
F. Table 3 and Figure 2A and B show the area percentages positively
stained for vimentin as a proportion of epithelial area per field. Raw
figures for each section are shown in Table S3. Epithelial expression
of the mesenchymal marker vimentin was significantly higher in the
SCD group (17.39% vs 6.65%, P = 0.003). Representative IHC
images are shown in Figure 2C‐H.
3.3 | Histological tissue scoring allows objective
assessment of fibrosis and inflammation and
correlation with EMT marker expression
As expected, all blocks containing stricture had significantly higher
total fibrosis scores than blocks containing no stricture (9.55 vs
5.11, P = 0.003; Table 4, Table S4). The mild to moderate scores
for NSCD blocks confirmed the field change effect of histological
fibrosis progression (Table S4). No dysplasia was found in any sec-
tion. Total ulcer scores, used as correlates for inflammation, were
TABLE 1 Clinical characteristics of nine patients with stricturing
ileal CD from which intestinal resection specimens were used across
immunohistochemistry and miRNA expression analysis studies
Characteristic Value
Gender
Male 3 (33.3)
Female 6 (66.7)
Median age at resection (IQR) (y) 33.8 (20)
Median disease duration at resection (IQR) (y) 10.5 (8)
Previous surgery
Yes 4 (44.4)
No 5 (55.6)
Smoking
Current 1 (11.1)
Previous 4 (44.4)
Never 4 (44.4)
Disease location
Ileal 5 (55.6)
Colonic 0 (0.0)
Ileocolonic 4 (44.4)
Upper GI 0 (0.0)
Disease behaviour
Inflammatory 0 (0.0)
Stricturing 9 (100.0)
Fistulating 0 (0.0)
Oral 5ASA Treatmenta
Yes 3 (33.3)
No 6 (66.7)
Oral steroid treatmenta
Yes 6 (66.7)
No 3 (33.3)
Thiopurine treatmenta
Yes 2 (22.2)
No 7 (77.8)
Methotrexate treatmenta
Yes 1 (11.1)
No 8 (88.9)
Infliximab treatmenta
Yes 1 (11.1)
No 8 (88.9)
Adalimumab treatmenta
Yes 1 (11.1)
No 8 (88.9)
Mean Hb (SD) (g/L) 129.0 (18.8)
Mean WCC (SD) (×109/L) 8.2 (3.7)
Mean CRP (SD) (mg/L) 15.6 (11.8)
Mean albumin (SD) (g/L) 38.8 (9.5)
Unless otherwise stated values represent total numbers, with values in
parentheses representing percentage.
IQR, interquartile range; SD, standard deviation; g, grams; mg, milligrams; L, litre.
aTreatment was either current or within the previous 3 mo of surgery.
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not significantly different between the two groups (P = 0.7;
Table 4).
This scoring system allowed the evaluation of correlations
between IHC scores and grades of fibrosis. Values of staining scores
of both cytokeratin‐18 and vimentin were plotted against corre-
sponding values of fibrosis scores. No correlation between vimentin
scores and composite fibrosis scores was demonstrated but a posi-
tive correlation was observed between cytokeratin‐18 IHC scores
and extent of subserosal fibrosis (R2 = 0.66, P < 0.001, Figure S2).
3.4 | The mir‐200 family is down‐regulated in
fibrotic CD intestinal tissue and specifically within the
epithelium
In conjunction with IHC evidence of EMT occurring in association
with fibrosis in intestinal resection specimens from patients with CD,
we also sought to measure expression of the miR‐200 family in eight
paired NSCD and SCD samples of whole tissue. The expression of
all five members of the miR‐200 family was measured using RT‐
qPCR and normalised to the expression of miR‐26b as the control
miRNA. Four of the five members of the miR‐200 family were found
to be down‐regulated in SCD tissue compared to NSCD tissue: miR‐
141 (P = 0.0022), miR‐200a (P = 0.0017), miR‐200c (P = 0.0015) and
miR‐429 (P = 0.0042). MiR‐200b expression also displayed a trend
towards down‐regulation in SCD tissue, although significance was
not reached (P = 0.1166) (Figure 3A).
Given the apparent regulatory role of the miR‐200 family in
EMT,31-33,35 we next sought to measure expression in different
intestinal tissue compartments in an independent cohort of SCD and
NSCD controls (n = 3 sample pairs). LCM was used to isolate regions
of epithelium and submucosa as well as smooth muscle as a control
TABLE 2 Clinical characteristics of patients from whom sera were
used for miRNA profiling studies
Characteristic NSCD group SCD group P value
Number of patients 29 13
Gender (%)
M 13 (44.8) 8 (61.5) 0.323
F 16 (55.2) 5 (38.5) 0.354
Median age (IQR) (y) 32 (17) 45 (28.5) 0.053
Median disease
duration (IQR) (y)
4 (6.1) 11 (12.3) 0.24
Disease location (%)
Ileal 14 (48.3) 6 (46.2) 0.901
Colonic 3 (10.3) 1 (7.6) 0.785
Ileocolonic 12 (41.4) 6 (46.2) 0.774
Upper GI 0 (0.0) 0 (0.0) 1.000
Disease behaviour (%)
Inflammatory 16 (55.2) 0 (0.0) 0.001
Stricturing 0 (0.0) 13 (100.0) <0.001
Penetrating 13 (44.8) 0 (0.0) 0.004
Median CDAI score (IQR) 135.5 (135.5) 135 (136.5) 0.59
Smoking status (%)
Current 6 (20.7) 6 (46.2) 0.095
Previous 2 (6.9) 2 (15.4) 0.392
Never 6 (20.7) 1 (7.6) 0.298
Unknown 15 (51.7) 4 (30.8) 0.214
Stricture present (%)
Yes 0 (0.0) 11 (84.6) <0.001
No 29 (100) 2 (15.4) <0.001
Current treatmenta (%)
5ASA 27 (93.1) 10 (77.0) 0.138
Antibiotics 7 (24.1) 3 (23.1) 0.945
Thiopurines 12 (41.4) 8 (61.5) 0.234
Anti‐TNFα 10 (34.5) 4 (30.8) 0.816
Sera and clinical details were made available from collaborators in Pavia,
Italy. An intestinal stricture was present in eleven of the patients in the
stricturing phenotype group, with two patients in this group having had a
stricture resected previously. Unless otherwise stated, values represent
total number, with percentages in brackets.
NSCD, non‐stricturing Crohn's disease; SCD, stricturing Crohn's disease;
M, male; F, female; IQR, interquartile range; CDAI, Crohn's disease activ-
ity index; 5ASA, 5‐aminosalicylic acid.
aTreatment was either current or within the previous 3 months of sample
collection.
TABLE 3 Cytokeratin‐18 and vimentin staining profiles in NSCD
and SCD surgical resection specimens
Sample
Pair
Cytokeratin‐18 Extra‐epithelial
cells positively stained (%)
Vimentin Area positively
stained for per slide (%)
NSCD SCD NSCD SCD
1 0.59 1.94 0.00 5.53
2 0.25 0.35 7.21 10.49
3 0.00 0.64 12.67 27.16
4 0.08 0.39 4.17 6.00
5 0.21 0.24 4.57 12.78
6 0.04 0.20 9.34 27.51
7 0.04 0.08 2.76 27.62
8 0.06 0.26 10.12 24.83
9 0.06 0.29 8.98 14.58
Mean 0.15 0.49 6.65 17.39
SEM 0.06 0.19 1.35 3.13
Student's
t test
P = 0.043 P = 0.003
For cytokeratin‐18 the ImageJ program was used as described to count
the total number of cells and number of positively stained cells in 3 ran-
domly selected fields of ×20 magnification. The sum of the numbers of
cells for each field was totalled and a percentage of positive staining cells
calculated for each sample as shown below. For vimentin, the ImageJ
program was used to calculate the total area (in pixels) assessed and the
area positively stained for vimentin (in pixels) in three randomly selected
crypts and two randomly selected regions of one hundred consecutive
surface epithelial cells at ×20 magnification. The latter was expressed as
a percentage of the former. Each data point is an average of percentage
values across the three crypts and two surface epithelial areas for each
slide. The mean percentages are shown for each group (NSCD vs SCD)
and the standard error of the mean (SEM) with the P value as calculated
using a Student's t test showing statistical significance.
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compartment from each tissue section (Figure S3). As predicted RNA
yield was low, so standardisation of RNA input involved dissecting a
consistent area per tissue compartment (Table S5 shows the areas
harvested for each sample; Table S6 shows total area grouped by
NSCD and SCD samples). The expression data were also normalised
to miR‐16 to facilitate comparison of relative expression levels. Fig-
ure 3B‐D shows the expression of members of the miR‐200 family
in the epithelial, submucosal and smooth muscle compartments of
paired NSCD and SCD samples. Significant down‐regulation of four
of the five members of the miR‐200 family was observed within the
epithelium (Figure 3B) of SCD samples compared to NSCD samples
(miR‐141 fold change 0.21, P = 0.015; miR‐200a fold change 0.17,
P = 0.013; miR‐200b fold change 0.51, P = 0.090; miR‐200c fold
change 0.19, P = 0.002; miR‐429 fold change 0.42, P = 0.008).
Within the submucosal compartment (Figure 3C), miR‐200b was
found to be significantly down‐regulated in SCD samples compared
F IGURE 1 Cytokeratin‐18 immunohistochemical analysis. Nine paired FFPE samples of strictured and non‐strictured intestinal tissue from
patients with Crohn's disease (CD) were stained for cytokeratin‐18. Image J was used to analyse the number of extra‐epithelial cells within the
lamina propria and submucosa positive for cytokeratin‐18 as a proportion of the total number of cells within 3 randomly selected high power
fields per section. Panel A shows the paired percentage values of extra‐epithelial cells positive for cytokeratin‐18 staining in non‐strictured and
strictured samples. Panel B shows the mean percentage of extra‐epithelial cells positive for cytokeratin‐18 staining in strictured and non‐
strictured tissue. There is a significant increase in the number of positive extra‐epithelial cells in strictured tissue (P = 0.043). Bars represent
standard error of the mean (SEM). Panels C‐F, representative images of immunohistochemical staining demonstrating specific positivity for
cytokeratin‐18 within the epithelium of non‐strictured (C, ×9.1; B, ×40) and strictured (E, ×16; F, ×40) intestinal sections from patients with
fibrostenosing CD. Panel D shows the area highlighted in panel C by the black rectangle at a higher power magnification. Panels C and D
demonstrate the lack of extra‐epithelial staining of cytokeratin18 in a representative non‐strictured intestinal sample. Panel F shows the area
highlighted in panel E by the black rectangle at a higher power magnification. Panels E and F are representative images from strictured intestinal
samples demonstrating two positive cellular extra‐epithelial staining patterns of cytokeratin18: membranous and cytoplasmic
6 | MEHTA ET AL.
to NSCD samples (fold change 0.55; P = 0.0432), whereas the other
four members were not (miR‐141 fold change 0.65, P = 0.087; miR‐
200a fold change 0.59, P = 0.073; miR‐200c fold change 0.55,
P = 0.056; miR‐429 fold change 0.60, P = 0.21). No significant differ-
ence in expression of any miR‐200 family member was observed in
the smooth muscle compartment (Figure 3D) between NSCD and
SCD samples (miR‐141 fold change 1.05, P = 0.900; miR‐200a fold
change 0.88, P = 0.735; miR‐200b fold change 0.78, P = 0.433; miR‐
200c fold change 0.77, P = 0.408; miR‐429 fold change 0.74,
P = 0.365).
3.5 | Epithelial down‐regulation of miR‐141 is
associated with the histological degree of fibrosis in
intestinal CD samples
The histological scoring system allowed a comparison of the fibrosis
grade to the compartmental expression of the miR‐200 family in the
cohort of SCD patients used for the LCM study. A negative correla-
tion was observed between epithelial miR‐141 expression and sub-
serosal fibrosis score (n = 3 sample pairs, R2 = 0.75, P = 0.02,
Figure 3E). Increased cycle threshold values (and therefore reduced
F IGURE 2 Vimentin
immunohistochemical analysis. Nine paired
FFPE samples of strictured and non‐
strictured intestinal tissue from patients
with Crohn's disease (CD) were stained for
vimentin. Image J was used to analyse the
area (in pixels) positive for vimentin as a
proportion of the total area (in pixels)
assessed within 2 randomly selected
regions of 100 consecutive surface
epithelial cells and 3 randomly selected
whole crypts in each section of 9 sample
pairs. Panel A shows the paired percentage
values of area positive for vimentin
staining in non‐strictured and strictured
samples. Panel B shows the mean
percentage of area positive for vimentin
staining in strictured and non‐strictured
tissue. There is a significant increase in the
percentage of area positively stained for
vimentin in the strictured specimens
compared to the non‐strictured specimens
(P = 0.003). Bars represent standard error
of the mean (SEM). **P < 0.01. Panels C‐
H, immunohistochemical staining
demonstrating specific positivity for
vimentin within the lamina propria and
submucosa of non‐strictured (C, ×0.6; D,
×20; E, ×20) and strictured (F, ×0.6; G,
×20; H, ×20) intestinal sections from
patients with CD. Panels D and E show
the areas of surface epithelium and crypts
highlighted in panel C by the black
rectangle, respectively, at a higher
magnification. Panels G and H show the
areas of surface epithelium and crypts
highlighted in panel F by the black
rectangle, respectively, at a higher
magnification. Both the surface epithelium
and crypt epithelium show higher positive
staining in the strictured specimens than in
the non‐strictured specimens
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expression) of miR‐141 appeared to be associated with higher sub-
serosal fibrosis scores, which were composite scores of both the
extent and severity of subserosal fibrosis. No significant correlation
was observed between the compartmental expression of any other
miRNA and histological fibrosis score parameter (Table S7).
3.6 | Known EMT effectors and downstream
targets of the miR‐200 family are dysregulated in
fibrotic CD intestinal tissue
The expression of transcriptional effectors of EMT and known
downstream targets of miR‐141 and the other members of the miR‐
200 family was measured in the same cohort of eight matched sam-
ple pairs in which miR‐200 down‐regulation had been demonstrated
(Figure 3F). A significant body of evidence links a group of transcrip-
tion factors to the control of EMT by the miR‐200 family, including
ZEB1, ZEB2, SNAIL and TWIST.37,39,40 Using RT‐qPCR one such tran-
scription factor, ZEB1, was found to be significantly up‐regulated in
strictured tissue (P = 0.035) (Figure 3F). Another three transcription
factors were found to be up‐regulated but not significantly so: ZEB2
(P = 0.259), SNAIL (P = 0.101), TWIST (P = 0.173) (Figure 3F). Given
that miRNAs are negative gene regulators, this up‐regulation of the
downstream targets is in keeping with a functionally relevant miRNA
down‐regulation in fibrotic tissue.
3.7 | The miR‐200 family is lowly expressed in sera
of CD patients and profiles do not differ between
disease phenotypes
The observation that the miR‐200 family is down‐regulated within
the intestinal epithelium in SCD is potentially clinically relevant for
the development of biomarkers of intestinal fibrosis in CD, in that
the epithelium is readily sampled by endoscopic mucosal biopsy.
However, non‐invasive testing is clearly more desirable given the
potential risks with endoscopic procedures and the potential inacces-
sibility of small intestinal lesions. Therefore, given that serum miRNA
profiles can be stable over time and assayed successfully,31,37,41 the
expression of the miR‐200 family in the sera of patients with CD
was studied, with the aim to assess whether alterations in levels in
patients with SCD could be found. An independent cohort of 42 CD
patients (Table 2) was used to assess whether alterations in miR‐200
family levels could be identified in the serum of SCD patients. Serum
samples with significant degrees of haemolysis were excluded from
further analysis (Figure S4). No significant differences in expression
of the control gene U6 (P = 0.2639), miR‐141 (P = 0.1474), miR‐
200a (P = 0.5941), miR‐200b (P = 0.3249) or miR‐200c (P = 0.3749)
were observed between the clinical groupings (one‐way analysis of
variance; Figure 4).
4 | DISCUSSION
Although published data suggest a contribution of EMT to the devel-
opment of intestinal fibrosis in mouse models,30 there are only very
few reports of cellular EMT events in human CD.31,32,37 This is
mainly due to the inherent difficulties associated with such studies:
well‐phenotyped ex vivo samples are necessary and most commer-
cially available human intestinal cell lines are from malignant
tumours. Here, these limitations were addressed by using well‐char-
acterised samples from clearly defined CD patient groups.
IHC revealed no extra‐epithelial staining of e‐cadherin in any sur-
gical specimen (SCD or NSCD). However, the cytokeratin‐18 and
vimentin profiles lend support for EMT in CD samples. This possible
early loss of e‐cadherin during EMT in human sections suggests a
potential difference in staining patterns between published animal
model data and well characterised human intestinal tissue. E‐cad-
herin is important for cellular adhesion9 and the early loss of this
transmembrane protein might be a necessary initial step for subse-
quent EMT. This finding should prompt the use of a range of epithe-
lial markers (eg cytokeratin‐8, ‐17, ‐19 and EMA) instead of solely e‐
cadherin when working with human material.
The absolute percentages of extra‐epithelial cells positive for
cytokeratin‐18 were very low, perhaps because cytokeratin‐18 is
also lost relatively early in EMT. Given that tissue used in this study
was taken from clinically relevant strictures, it is likely that fibrosis
was at a late stage of development. It is also possible therefore that
fully transitioned cells will have been missed, or that the contribution
of EMT at this stage is less than at the initiatory stages of fibrosis.
In contrast, the epithelial vimentin staining percentage values were
relatively high, potentially representing a population of cells primed
for transitioning. It is possible that some of these positively stained
cells represented intra‐epithelial lymphocytes, although both NSCD
and SCD groups would have been affected by this to a similar
degree given that the histological inflammation scores were not sig-
nificantly different between the two groups. The acquisition of mes-
enchymal markers, therefore, may occur earlier in EMT than
purported, and certainly earlier than in animal models.30 These find-
ings challenge the traditional view of EMT as a linear progression of
cells losing epithelial characteristics before transitioning into mes-
enchymal cells. Furthermore, the morphology of extra‐epithelial cells
positive for cytokeratin‐18 were neither of classical mesenchymal
nor epithelial appearance, in keeping with the theory of “partial
EMT”.29 Indeed, this intermediate state of transitioning cell is
TABLE 4 Total histological fibrosis and ulcer scores
Mean total
fibrosis score SE
Mean total
ulcer score SE
NSCD 5.11 1.03 1.77 0.79
SCD 9.55 0.53 2.22 0.89
P value 0.003 0.70
Nine sample sets of archived small intestinal specimens from patients
with CD were graded by an independent gastrointestinal histopathologist
who was blinded to clinicopathological details and given total fibrosis
and total ulcer scores. The mean total fibrosis scores were significantly
higher in the stricture sets than the non‐stricture sets, with no significant
difference in the total ulcer scores between the two groups.
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thought to occur more frequently in fibrosis‐related EMT than can-
cer‐related EMT.27,29
The significant alterations in EMT cellular marker expression
between NSCD and SCD tissue occurred in sample groups between
which objective inflammatory scores were not significantly different.
This contrasts with previous data showing reduced e‐cadherin
expression and increased vimentin expression in inflamed colonic
mucosal biopsy samples from patients with IBD.36 It is unclear
F IGURE 3 MiR‐200 family and EMT transcription factor expression in strictured and non‐strictured Crohns disease small intestine. Panel A,
MicroRNA‐200 family expression assessed using RT‐qPCR on RNA extracted from eight matched paired NSCD (black) and SCD (grey) tissue
samples. Fold changes of normalised expression of each of the five members of the miR‐200 family in SCD samples compared to NSCD samples
is shown. Fold changes were calculated using the 2−δδCT method. Four of the five members of the miR‐200 family were significantly down‐
regulated: miR‐141 (P = 0.0022), miR‐200a (P = 0.0017), miR‐200c (P = 0.0015) and miR‐429 (P = 0.0042). Bars represent mean values with
standard error. **P < 0.01. Panel B‐D, MiR‐200 family expression by tissue compartment. Panel B shows fold change of normalised expression
of each of the five members of the miR‐200 family in the epithelial compartment of SCD samples compared to NSCD samples. Four of the five
members of the miR‐200 family were significantly down‐regulated: miR‐141 (P = 0.0151), miR‐200a (P = 0.01310), miR‐200c (P = 0.0015) and
miR‐429 (P = 0.0080). Panel C shows fold change of normalised expression of each of the five members of the miR‐200 family in the
submucosal compartment of SCD samples compared to NSCD samples. MiR‐200b was found to be significantly down‐regulated in SCD samples
in this compartment (P = 0.0432). No other member of the miR‐200 family was significantly differentially expressed. There was no significant
difference found in the expression of any member of the miR‐200 family within the smooth muscle compartment (D). Fold changes were
calculated using the 2−δδCT method. Bars represent mean values with standard error. * P < 0.05, ** P < 0.01. Panel E, correlation between
subserosal fibrosis score and epithelial expression of miR‐141 in CD small intestinal tissue. The combination of subserosal fibrosis extent and
severity (the subserosal fibrosis score) as assigned by an independent expert gastrointestinal histopathologist blinded to clinicopathological
details are plotted against the Ct values of miR‐141 in six samples of SCD and NSCD intestinal tissue. A positive correlation is observed
(R² = 0.75, P = 0.02). Panel F, EMT transcription factor expression. RT‐qPCR was performed on RNA extracted from eight matched sample pairs
of strictured (grey bars) and non‐strictured (black bar) small intestinal tissue from patients with fibrostenosing CD. Fold changes were calculated
using the 2−δδCT method normalised to GAPDH. ZEB1 was found to be significantly up‐regulated (P = 0.035). Three other transcription factors
were not significantly up‐regulated: ZEB2 (P = 0.259), SNAIL (P = 0.101), TWIST (P = 0.173). Bars represent mean standard error. *P < 0.05
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whether the specimens in that study also had evidence of fibrosis,
although this would seem less likely given that patients with UC
were included and all samples were colonic, rather than ileal, in ori-
gin. In addition, the samples in the present study were chosen care-
fully to avoid including dysplasia or established cancer, given the
well‐characterised association of EMT with gastrointestinal cancer
progression. Therefore, it can be assumed that the EMT marker
alterations demonstrated here were not being driven by malignancy
or inflammation.
The histological fibrosis scoring system used here was not vali-
dated on an external cohort, nor by a second pathologist. Despite
these limitations, a significant correlation was observed between
cytokeratin‐18 expression and the degree of subserosal fibrosis. This
would seem counterintuitive given that, at a tissue level, the epithe-
lial origin of transitioning cells and the serosa are some distance
apart. It is possible, therefore, that the contribution of EMT to
intestinal fibrosis is minimal or that it occurs in ways other than the
delivery of active matrix‐producing cells. In models of renal fibrosis,
injured epithelial cells have been found to undergo partial EMT but
remain close to the tubular epithelium and secrete cytokines and
exosomes that aid fibrocyte recruitment and macrophage stimula-
tion.27,28,42 It is possible that a similar paradigm exists in the gut,
whereby epithelial cells undergoing partial EMT modulate fibrosis in
the interstitium by paracrine, rather than migratory and matrix‐
producing, functions. The extra‐epithelial cells identified by cytoker-
atin‐18 staining could therefore represent “stranded” epithelial cells
following end‐stage fibrosis, “partial” EMT cells effecting fibrosis
through paracrine channels or “migrant” cells invading deeper tissue
layers for matrix deposition. Further work is required to clarify this.
Dysregulation of miRNA‐200 family members was shown to
occur not only between NSCD and SCD tissue, but within the
epithelial layer specifically. This is a novel finding, and one which
makes biological sense as the altered miRNA expression is juxta-
posed to the origin of transitioning cells. Given the relatively small
sample size, this finding should be explored in larger throughput
studies. In addition, significant negative correlation was found
between miR‐141 expression and the subserosal fibrosis score.
Hence, alterations in molecular expression within the superficial
mucosa may reflect cellular events occurring within deeper intestinal
layers in CD, evidence for which has been presented before.43 Con-
versely, no correlation was found between the remaining members
of the miR‐200 family and the other parameters of histological fibro-
sis. This relatively limited correlation may be due to the fact that
alterations in miRNA levels may be only early events in the process
of EMT, or simply a function of the small sample size.
The up‐regulation in ZEB1 expression in SCD samples makes bio-
logical sense given that miRNAs are negative gene regulators. The
principal gene target of ZEB1 is CDH1, which codes for e‐cadherin.
F IGURE 4 Serum expression profiles of
the miR‐200 family in patients with
Crohn's disease and healthy controls.
MiRNAs were extracted from sera from
patients with stricturing CD (SCD; n = 10),
non‐stricturing CD (NSCD; n = 23) and
healthy controls (HC; n = 12). Box and
whisker plots demonstrate relative
expression of U6 (A), miR‐141 (B), miR‐
200a (C), miR‐200b (D) and miR‐200c (E).
One way ANOVA testing revealed no
significant differences between the clinical
groups for any member of the miR‐200
family nor the control U6. Mir‐429 was
excluded from this analysis as correlation
between duplicate readings was poor. AU,
arbitrary units; HC, healthy controls;
NSCD, non‐stricturing Crohn's disease;
SCD, stricturing Crohn's disease
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Loss of e‐cadherin and subsequent cellular adhesion is a hallmark of
EMT 16,29,44 and this may occur under the control of the miR‐200
family via the transcription factors ZEB1 and perhaps also ZEB2,
SNAIL and TWIST; this loss may be an “EMT trigger” in this setting.
Further work is clearly required to demonstrate a functional link
between the miR‐200 family and control of type 2 EMT in the intes-
tine.
If this mechanism was supported by further studies, potential
therapeutic strategies may involve miRNA manipulation. For exam-
ple, recent work has demonstrated that microvesicle‐delivered miR‐
200b reduces colonic fibrosis in TNBS‐induced experimental colitis.45
Furthermore, preclinical trials that assess the therapeutic impact of
targeting miRNAs have already begun.46,47 Limitations to therapeutic
use of miRNA modulation, include off‐target effects48-50 and drug
delivery, which is a particular problem when dealing with the gas-
trointestinal tract.
Serum expression of the miR‐200 family did not differ between
healthy controls, NSCD or SCD, possibly due to an overlap of fibro-
tic burden or generally low miR‐200 expression levels. The miR‐200
family is likely to be functionally relevant in CD fibrosis, but does
not appear to be amenable to non‐invasive serum sampling for
assessment of fibrotic burden or monitoring therapeutic intervention.
The focus of future research therefore should be on improving the
understanding of the processes underpinning intestinal fibrosis and
identifying potential therapeutic targets.
In conclusion, our results indicate the occurrence of EMT in
fibrotic intestinal CD tissue, and that this occurs independently of
the effect of inflammation. Additional work is now required to con-
firm these findings using a wide range of epithelial and mesenchymal
markers. The miR‐200 family, known regulators of EMT in other
organs, are dysregulated in fibrotic CD intestine, and this dysregula-
tion is specific to the epithelium. Functional studies, together with
further larger scale studies using similarly well‐phenotyped samples
are warranted.
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